<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573102</url>
  </required_header>
  <id_info>
    <org_study_id>SGLT2 antiproteinuric effect</org_study_id>
    <nct_id>NCT03573102</nct_id>
  </id_info>
  <brief_title>Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients</brief_title>
  <official_title>Effect of SGLT2 Inhibitor on Proteinuria in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nahla H Tohami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes Mellitus is the leading cause of end stage renal disease. As proven by many studies
      , controlling proteinuria can delay the progression to end stage renal disease.This work will
      study the effect of sodium glucose co transporter 2 inhibitor , a new antihyperglycemic drug
      , on proteinuria and to compare its effect with the effect of classic antiproteinuric drugs
      as angiotensin converting enzyme inhibitor , aspirin and statins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic nephropathy involves progressive stages including glomerular hyperfilteration ,
      microalbuminuria , overt proteinuria and a decline in glomerular filteration rate leading to
      end stage renal disease.

      Despite all the available interventions available for diabetic patients including tight
      glycemic control , and blood pressure control , using angiotensin converting enzyme
      inhibitors, angiotensin II receptor antagonist renal disease remains prevalent and progress
      in these patients.

      The newer therapy of diabetes is the use of sodium glucose cotransporter 2 inhibitor as it
      has the potential of renoprotection in patients with diabetic nephropathy just as ACEI and
      ARBS to reduce glomerular hyperfilteration .This action may reduce albuminuria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>decrease in proteinuria</measure>
    <time_frame>6 months</time_frame>
    <description>improvement of proteinuria in patients receiving dapagliflozine</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACE inhibitor , aspirin , statins will be given once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cases</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGLT2 inhibitors will be given with classic antiproteinuric drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT2 inhibitor</intervention_name>
    <description>SGLT2 inhibitor 10 mg/day</description>
    <arm_group_label>cases</arm_group_label>
    <other_name>ACE Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitor</intervention_name>
    <description>ACE inhibitor once daily</description>
    <arm_group_label>cases</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>Aspirin , statins</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients with type 2 diabetes.

          -  controlled diabetes.

          -  patients with proteinuria

        Exclusion Criteria:

          -  patients with proteinuria due to other disease.

          -  patients with HbA1c &gt;8%.

          -  patients with uncontrolled hypertension.

          -  patients with chronic liver disease.

          -  patients with type 1 diabetes .

          -  patients already on the same drug ( dapagliflozine).

          -  patients with raised serum creatinine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magdy Sharkawy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magdy Sharkawy, MD</last_name>
    <phone>00201001422331</phone>
    <email>magdi35@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nahla H Tohami, MSc</last_name>
    <phone>00201003771280</phone>
    <email>nahlatohami@med.asu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain Shams University Hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nahla H Tohami, MD</last_name>
      <phone>1003771280</phone>
      <email>dr.nahlahussein@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Magdy Mohamed Saeed El Sharkawy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Lotfy M, Adeghate J, Kalasz H, Singh J, Adeghate E. Chronic Complications of Diabetes Mellitus: A Mini Review. Curr Diabetes Rev. 2017;13(1):3-10. doi: 10.2174/1573399812666151016101622. Review.</citation>
    <PMID>26472574</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>April 18, 2020</last_update_submitted>
  <last_update_submitted_qc>April 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Nahla H Tohami</investigator_full_name>
    <investigator_title>Assistent lecturer of nephrology</investigator_title>
  </responsible_party>
  <keyword>proteinuria , SGLT2 inhibitors , diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>June 23, 2020</submitted>
    <returned>July 8, 2020</returned>
    <submitted>July 19, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

